Compass Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 5, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 5, 2025

CMPX$0.84+0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets (Unaudited)

(In thousands, except par value)

	September 30, 2025 (unaudited)	December 31, 2024 (Note 1)
Assets
Current assets:
Cash and cash equivalents	$46,212	$43,483
Marketable securities	173,683	83,239
Prepaid expenses and other current assets	1,225	6,029
Total current assets	221,120	132,751
Property and equipment, net	119	353
Operating lease, right-of-use ("ROU") asset	9,452	6,731
Restricted cash	568	568
Total assets	$231,259	$140,403
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$3,095	$2,249
Accrued expenses	8,684	6,287
Operating lease obligations, current portion	633	338
Total current liabilities	12,412	8,874
Operating lease obligations, long-term portion	9,234	6,296
Total liabilities	21,646	15,170
Commitments and contingencies (Note 7)
Stockholders' equity:
Common stock, $0.0001 par value: 300,000 shares authorized; 177,572 and 137,820 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively	53	14
Additional paid-in-capital	624,742	489,692
Accumulated other comprehensive income	274	210
Accumulated deficit	(415,456)	(364,683)
Total stockholders' equity	209,613	125,233
Total liabilities and stockholders' equity	$231,259	$140,403

**Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.